Skip to content
Biotechnology

Moolec Confirms US Harvest and Promising Yields for Plant-Grown Products GLASO(TM) and Piggy Sooy(TM) in October

Moolec Science SA 2 mins read

LUXEMBOURG / ACCESSWIRE / September 5, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024.

GLASO™ and Piggy Sooy™ US Harvest Announcement
GLASO™ and Piggy Sooy™ US Harvest Announcement

GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted acres of genetically modified safflower, mainly for commercial purposes. As a result of the harvest, Moolec is expecting to produce between 300 to 400 tons of safflower seeds that contain high levels of GLA. To allocate most of the upcoming GLASO™ production, Moolec has secured an offtake agreement with a major global CPG company, targeting the US market in 2025. Following a successful and rigorous audit from Moolec's CPG customer, production is set to begin in late 2024.

The Company is also developing a broader commercial strategy to reach larger markets and clients. Moolec's GLASO™ product contains almost 3 times more GLA than conventional sources such as borage and primrose oil, making it the most concentrated GLA oil available on the market.

Piggy Sooy™ (porcine myoglobin in soybean seeds) field trials are being carried out in 3 different US locations: Ohio, Missouri and Iowa. Main purposes for the campaign are product development (sampling), seed increase and gathering of environmental and regulatory data to continue Moolec's US-FDA approval pathway. The Team also projects a remarkable first open field performance for its bioengineered soybean Piggy Sooy™ after recent approval for cultivation from USDA-APHIS. This has set an unprecedented milestone in biotechnology last April, with Moolec becoming the first Molecular Farming company to obtain this kind of clearance for food crops growing animal proteins in US territory.

Chief Technology Officer and Co-Founder Martín Salinas stated: "Our commitment to scaling Moolec's Molecular Farming Technology is demonstrated by our GLASO™ campaign and the field trials of Piggy Sooy™. These efforts not only reinforce our position as pioneers in the industry but also lay the foundation for sustainable solutions in agriculture and biotechnology." He then finished by remarking: "One acre of Piggy Sooy™ could potentially produce pork meat proteins equivalent to 10 pigs, reducing water footprint, land usage and CO2 emissions. This is a clear demonstration on how we promote environmental improvements throughout all our operations. Our aim is to heal the meat production system."

Contact Information

Press & Media
[email protected]

Investor Relations
[email protected]

Related Files

Moolec Confirms US Harvest And Promising Yields For Plant-Grown Products GLASO™ And Piggy Sooy™ In October - 2024.09.05

SOURCE: Moolec Science

.

View the original press release on newswire.com.

More from this category

  • Biotechnology
  • 11/07/2025
  • 11:39
OncoSil Medical Limited (ASX:OSL)

OncoSil Medical (ASX:OSL) announces appointment of Non-Executive Director

Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) is pleased to announce the appointment of Dr Thomas Duthy as a Non-Executive Director, effective 11 July 2025. Dr Duthy brings more than 21 years of experience across financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. He was previously Head of Corporate Development and Investor Relations at Sirtex Medical (ASX:SRX), where he played a key role in its $1.9 billion acquisition, the largest medical device transaction in Australian history. Dr Duthy is the Founder and Director of Nemean Group, a corporate advisory firm serving healthcare…

  • Biotechnology, Business Company News
  • 08/07/2025
  • 10:02
Jane Morgan Management

BlinkLab Expands U.S. Clinical Trial Network – University of Nebraska Medical Center Engaged as Second Site in Main Phase of FDA 510(k) Study

BlinkLab Limited (ASX:BB1) (“BlinkLab” or “the Company”) is pleased to announce the expansion of its U.S. clinical trial network with the University of Nebraska Medical Center (UNMC) engaged as the second site in the main phase of its FDA 510(k) study for BlinkLab Dx 1 – its smartphone-based diagnostic tool for early autism detection. Highlights Second U.S. Site: University of Nebraska Medical Center (UNMC) selected as second site for BlinkLab’s pivotal FDA 510(k) autism diagnostic trial. Pilot Phase Near Completion: BlinkLab’s 100-participant pilot study has been progressing towards completion, with results expected this quarter. Main Study Scaling: An additional 750–900…

  • Contains:
  • Biotechnology, Research Development
  • 08/07/2025
  • 06:00
Palin Communications

Taiwanese enterprises helping to make Australian health and wellbeing innovations a reality

Call continues for Australian submissions to “Go Healthy with Taiwan” 8 July 2025: The Taiwan Trade Centre in Sydney is continuing to encourage Australian…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.